Bio-Rad Laboratories (NYSE:BIO.B) Lowered to C+ at TheStreet

Bio-Rad Laboratories (NYSE:BIO.B – Get Rating) was downgraded by TheStreet from a “b” rating to a “c+” rating in a note issued to investors on Thursday, TheStreetRatingsTable reports.

NYSE BIO.B opened at $507.99 on Thursday. Bio-Rad Laboratories has a twelve month low of $321.42 and a twelve month high of $538.00. The stock has a market capitalization of $15.20 billion, a PE ratio of -104.10 and a beta of 0.73. The stock has a 50-day simple moving average of $578.76 and a 200 day simple moving average of $658.29.

Bio-Rad Laboratories (NYSE:BIO.B – Get Rating) last posted its quarterly earnings data on Thursday, February 10th. The company reported $3.21 earnings per share for the quarter. Bio-Rad Laboratories had a return on equity of 3.70% and a net margin of 145.28%. The business had revenue of $732.77 million during the quarter.

Bio-Rad Laboratories Company Profile (Get Rating)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Recommended Stories